Background: Recently the role of bacteria in acute exacerbations of chronic bronchitis (AECB) as well as antibiotic treatment with selected drugs, especially fluoroquinolones, have been better defined. Objective: To assess the efficacy and safety in patients with AECB of prulifloxacin in comparison with ciprofloxacin. Methods: AECB was defined according to the guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections (1992). 235 patients took part in the trial; 117 (88 males and 29 females, mean age 64.8 years) received 600 mg prulifloxacin once daily and 118 (91 males and 27 females, mean age 64.5 years) 500 mg ciprofloxacin twice a day, for a duration of 10 days. The study design was randomized, multicenter, double-blind, double-dummy. Efficacy evaluations were performed by comparing pretreatment and posttreatment assessments. The clinical response was determined by 4-point rating scores on cough, dyspnea, and expectoration (volume and appearance). The microbiological response was assessed on sputum specimen. Results: Clinical success was observed in 84.7 and 85% of patients in the prulifloxacin and ciprofloxacin groups, respectively. The 95% confidence interval proved the equivalence of treatments. Both drugs successfully eradicated the most commonly isolated strains, including Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and Pseudomonas aeruginosa. Both treatments were well tolerated. Adverse drug reactions were always of mild or moderate intensity. Conclusion: The study showed that a 10-day course of prulifloxacin is as effective and safe as ciprofloxacin in the treatment of patients with AECB.

Keywords:
Chronic bronchitis, acute exacerbation, Ciprofloxacin, Prulifloxacin, Fluoroquinolones
1.
Adams SG, Melo J, Luther M, Anzueto A: Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345–1352.
2.
Niederman MS: Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000;15:59–70.
3.
Adams SG, Anzueto A: Antibiotic therapy in acute exacerbation of chronic bronchitis. Semin Respir Infect 2000;15:234–247.
4.
Campbell GD Jr: The role of antimicrobial therapy in acute exacerbations of chronic bronchitis. Am J Med Sci 1999;318:84–88.
5.
Balter MS, Hyland RH, Low DE, et al: Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994;151:5–23.
6.
Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380S–385S.
7.
Grossman RF: The role of fluoroquinolones in respiratory tract infections. J Antimicrob Chemother 1997;40:59–62.
8.
Ozaki M, Matsuda M, Tommii Y, Kimura K, Kazuno K, Kitano M: In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother 1991;35:2490–2495.
9.
Yoshida T, Mitsuhashi S: Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 1993;37:793–800.
10.
Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A: Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998;26:355–359.
11.
Montanari MP, Mingoia M, Varaldo PE: In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin against nosocomial and community Italian isolates. Antimicrobial Agents Chemother 2001;45:3616–3622.
12.
Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS: General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992;15:S62–S88.
13.
Bartlett JG, Brewer NS, Ryan KJ: Laboratory diagnosis of lower respiratory tract infections; in Washington JA (ed): Cumitech 7. Washington, American Society for Microbiology, 1987, pp 1–15.
14.
National Committee for Clinical Laboratory Standard: Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2-A6, ed 6. Wayne, NCCLS, 1997.
15.
Committee for Proprietary Medicinal Products, Points to consider on biostatistical/methodological issue arising from recent CPMP discussion on licensing applications: Superiority, non-inferiority and equivalence CPMP/EWP/482/99, London, 1999.
16.
Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence: The importance of rigorous methods. BMJ 1996;313:36–39.
17.
Hauck WW, Anderson S: Some issues in the design and analysis of equivalence trials. Drug Inf J 1999;33:109–118.
18.
Wilson R, Kubin R, Ballin I, Deppermann KM, Bassaris HP, Leophonte P, Schreurs AJ, Torres A, Sommerauer B: Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501–513.
19.
Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316–1320.
20.
Destache CJ, Dewan N, O’Donohue WJ, Campbell JC, Angelillo VA: Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;43:107–113.
21.
Bertino J Jr, Fish D: The safety profile of the fluoroquinolones. Clin Ther 2000;22:798–817.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.